PT3581654T - Métodos e composições para a inibição específica de glicolato oxidase (hao1) por rna de cadeia dupla - Google Patents

Métodos e composições para a inibição específica de glicolato oxidase (hao1) por rna de cadeia dupla

Info

Publication number: PT3581654T
Authority: PT; Portugal
Prior art keywords: hao1; compositions; methods; double chain; specific inhibition
Prior art date: 2013-12-27

Application number

PT191826163T

Other languages

English (en)

Portuguese (pt)

Original Assignee

Dicerna Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-27

Filing date

2014-12-26

Publication date

2021-06-02

2014-12-26 Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc

2021-06-02 Publication of PT3581654T publication Critical patent/PT3581654T/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
- C12Y101/03015—(S)-2-Hydroxy-acid oxidase (1.1.3.15)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Enzymes And Modification Thereof (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PT191826163T 2013-12-27 2014-12-26 Métodos e composições para a inibição específica de glicolato oxidase (hao1) por rna de cadeia dupla PT3581654T (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361921181P	2013-12-27	2013-12-27
US201461937838P	2014-02-10	2014-02-10

Publications (1)

Publication Number	Publication Date
PT3581654T true PT3581654T (pt)	2021-06-02

Family

ID=53479713

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT191826163T PT3581654T (pt)	2013-12-27	2014-12-26	Métodos e composições para a inibição específica de glicolato oxidase (hao1) por rna de cadeia dupla

Country Status (21)

Country	Link
US (7)	US9701966B2 (2)
EP (3)	EP3581654B1 (2)
JP (2)	JP6886818B2 (2)
AU (2)	AU2014369850B2 (2)
CA (1)	CA2935220A1 (2)
CY (2)	CY1124203T1 (2)
DK (2)	DK3087184T3 (2)
ES (2)	ES2749855T3 (2)
FI (1)	FIC20210025I1 (2)
FR (1)	FR21C1044I2 (2)
HR (1)	HRP20210612T1 (2)
HU (2)	HUE055470T2 (2)
LT (2)	LT3581654T (2)
LU (1)	LUC00218I2 (2)
NO (1)	NO2021038I1 (2)
PL (1)	PL3581654T3 (2)
PT (1)	PT3581654T (2)
RS (1)	RS61892B1 (2)
SI (1)	SI3581654T1 (2)
SM (1)	SMT202100325T1 (2)
WO (1)	WO2015100436A1 (2)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9228186B2 (en)	2002-11-14	2016-01-05	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
US9879266B2 (en)	2002-11-14	2018-01-30	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
EP3581654B1 (en)	2013-12-27	2021-03-31	Dicerna Pharmaceuticals, Inc.	Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna
TW202503057A (zh) *	2014-10-10	2025-01-16	美商艾爾妮蘭製藥公司	用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
EP3310918B1 (en) *	2015-06-18	2020-08-05	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2018065303A1 (en) *	2016-10-05	2018-04-12	Syngenta Participations Ag	Methods of preserving the biological activity of ribonucleic acids
CA3043768A1 (en)	2016-11-29	2018-06-07	PureTech Health LLC	Exosomes for delivery of therapeutic agents
CA3069451A1 (en)	2017-07-13	2019-01-17	Alnylam Pharmaceuticals, Inc.	Methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
MX2021001070A (es) *	2018-07-31	2021-05-27	Intellia Therapeutics Inc	Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1).
WO2020132659A1 (en) *	2018-12-21	2020-06-25	Precision Biosciences, Inc.	Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
AU2020376792B2 (en)	2019-11-01	2025-10-02	Lilac Therapeutics, Inc.	Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
US20230242918A1 (en) *	2020-05-22	2023-08-03	President And Fellows Of Harvard College	Interferon- inducing oligonucleotide duplexes and methods of use
JP7642809B2 (ja)	2020-11-12	2025-03-10	プレシジョンバイオサイエンシズ，インク．	ジストロフィン遺伝子内の認識配列に特異性を有する遺伝子操作されたメガヌクレアーゼ
EP4043018A1 (en)	2021-02-10	2022-08-17	Charité - Universitätsmedizin Berlin	Composition and method for reducing oxalate levels in patients receiving maintenance dialysis
IL308803A (en) *	2021-06-04	2024-01-01	Arbor Biotechnologies Inc	Gene editing systems comprising guide RNA targeting hydroxy acid oxidase 1 (HAO1) and uses thereof
WO2023003805A1 (en) *	2021-07-19	2023-01-26	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
CN117041337A (zh) *	2023-08-14	2023-11-10	中国电信股份有限公司技术创新中心	网络流量的处理方法、系统以及risc装置
EP4725949A1 (en) *	2024-10-08	2026-04-15	BioSpring Gesellschaft für Biotechnologie mbH	Improved solid-phase phosphoramidite-synthesis of long oligonucleotide molecules

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US513207A (en)		1894-01-23		Rail-brake
US5432272A (en)	1990-10-09	1995-07-11	Benner; Steven A.	Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
ES2061416T3 (es)	1990-10-12	1997-03-01	Max Planck Gesellschaft	Ribozimas modificadas.
US5652094A (en)	1992-01-31	1997-07-29	University Of Montreal	Nucleozymes
US6469158B1 (en)	1992-05-14	2002-10-22	Ribozyme Pharmaceuticals, Incorporated	Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5977343A (en)	1992-05-14	1999-11-02	Ribozyme Pharmaceuticals, Inc.	Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en)	1992-05-14	1998-09-08	Ribozyme Pharmaceuticals, Inc.	Deprotection of RNA with alkylamine
ATE227342T1 (de)	1993-09-02	2002-11-15	Ribozyme Pharm Inc	Enzymatische nukleiksaüre die nicht-nukleotide enthaltet
US5889136A (en)	1995-06-09	1999-03-30	The Regents Of The University Of Colorado	Orthoester protecting groups in RNA synthesis
US5998203A (en)	1996-04-16	1999-12-07	Ribozyme Pharmaceuticals, Inc.	Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6218108B1 (en)	1997-05-16	2001-04-17	Research Corporation Technologies, Inc.	Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US6248878B1 (en)	1996-12-24	2001-06-19	Ribozyme Pharmaceuticals, Inc.	Nucleoside analogs
US6111086A (en)	1998-02-27	2000-08-29	Scaringe; Stephen A.	Orthoester protecting groups
US7678897B2 (en) *	2002-02-20	2010-03-16	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
WO2006006948A2 (en)	2002-11-14	2006-01-19	Dharmacon, Inc.	METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9879266B2 (en) *	2002-11-14	2018-01-30	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
AU2003295600A1 (en)	2002-11-14	2004-06-15	Dharmacon, Inc.	Functional and hyperfunctional sirna
CA2559955C (en)	2004-03-15	2016-02-16	City Of Hope	Methods and compositions for the specific inhibition of gene expression by double-stranded rna
US20070265220A1 (en)	2004-03-15	2007-11-15	City Of Hope	Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
WO2005116204A1 (ja)	2004-05-11	2005-12-08	Rnai Co., Ltd.	Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
US20080213891A1 (en)	2004-07-21	2008-09-04	Alnylam Pharmaceuticals, Inc.	RNAi Agents Comprising Universal Nucleobases
WO2007030167A1 (en)	2005-09-02	2007-03-15	Nastech Pharmaceutical Company Inc.	Modification of double-stranded ribonucleic acid molecules
US8178503B2 (en) *	2006-03-03	2012-05-15	International Business Machines Corporation	Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
JP4644619B2 (ja)	2006-03-27	2011-03-02	富士通株式会社	基地局装置、端末および帯域制御方法
DE102007021853A1 (de)	2007-05-10	2008-11-13	Norma Germany Gmbh	Steckkupplung und Stutzen für eine Steckkupplung
US20110288147A1 (en)	2008-09-22	2011-11-24	Bob Dale Brown	Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop
CN101752443B (zh)	2008-12-08	2012-06-20	鸿富锦精密工业（深圳）有限公司	光伏电池
US20100249214A1 (en)	2009-02-11	2010-09-30	Dicerna Pharmaceuticals	Multiplex dicer substrate rna interference molecules having joining sequences
KR101728655B1 (ko)	2008-12-18	2017-04-19	다이서나 파마수이티컬, 인크.	유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
EP2756845B1 (en) *	2009-04-03	2017-03-15	Dicerna Pharmaceuticals, Inc.	Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
US8632982B2 (en) *	2009-05-21	2014-01-21	Institute For Systems Biology	Biomarkers for liver injury
EP3730618A1 (en)	2011-11-18	2020-10-28	Alnylam Pharmaceuticals, Inc.	Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
US9133461B2 (en) *	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
EP3581654B1 (en) *	2013-12-27	2021-03-31	Dicerna Pharmaceuticals, Inc.	Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna
TW202503057A (zh) *	2014-10-10	2025-01-16	美商艾爾妮蘭製藥公司	用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法

2014
- 2014-12-26 EP EP19182616.3A patent/EP3581654B1/en active Active
- 2014-12-26 RS RS20210652A patent/RS61892B1/sr unknown
- 2014-12-26 DK DK14874374.3T patent/DK3087184T3/da active
- 2014-12-26 CA CA2935220A patent/CA2935220A1/en active Pending
- 2014-12-26 US US14/583,200 patent/US9701966B2/en active Active
- 2014-12-26 PL PL19182616T patent/PL3581654T3/pl unknown
- 2014-12-26 EP EP21163279.9A patent/EP3892727A1/en not_active Withdrawn
- 2014-12-26 HU HUE19182616A patent/HUE055470T2/hu unknown
- 2014-12-26 SM SM20210325T patent/SMT202100325T1/it unknown
- 2014-12-26 LT LTEP19182616.3T patent/LT3581654T/lt unknown
- 2014-12-26 EP EP14874374.3A patent/EP3087184B1/en active Active
- 2014-12-26 AU AU2014369850A patent/AU2014369850B2/en active Active
- 2014-12-26 ES ES14874374T patent/ES2749855T3/es active Active
- 2014-12-26 PT PT191826163T patent/PT3581654T/pt unknown
- 2014-12-26 ES ES19182616T patent/ES2875558T3/es active Active
- 2014-12-26 DK DK19182616.3T patent/DK3581654T3/da active
- 2014-12-26 JP JP2016543143A patent/JP6886818B2/ja active Active
- 2014-12-26 WO PCT/US2014/072410 patent/WO2015100436A1/en not_active Ceased
- 2014-12-26 SI SI201431812T patent/SI3581654T1/sl unknown
2017
- 2017-06-07 US US15/616,254 patent/US9828606B2/en active Active
- 2017-10-25 US US15/793,441 patent/US10435692B2/en active Active
2019
- 2019-03-08 US US16/297,354 patent/US10487330B2/en active Active
- 2019-03-08 US US16/297,316 patent/US10465195B2/en active Active
- 2019-08-20 US US16/545,149 patent/US11060093B2/en active Active
- 2019-11-08 JP JP2019202937A patent/JP7109416B2/ja active Active
2021
- 2021-01-25 US US17/157,803 patent/US11873493B2/en active Active
- 2021-03-29 AU AU2021201953A patent/AU2021201953A1/en not_active Abandoned
- 2021-04-16 HR HRP20210612TT patent/HRP20210612T1/hr unknown
- 2021-05-28 CY CY20211100465T patent/CY1124203T1/el unknown
- 2021-08-18 LU LU00218C patent/LUC00218I2/fr unknown
- 2021-08-25 FI FIC20210025C patent/FIC20210025I1/fi unknown
- 2021-08-26 CY CY2021022C patent/CY2021022I2/el unknown
- 2021-09-01 LT LTPA2021008C patent/LTC3581654I2/lt unknown
- 2021-09-16 NO NO2021038C patent/NO2021038I1/no unknown
- 2021-09-20 FR FR21C1044C patent/FR21C1044I2/fr active Active
- 2021-09-28 HU HUS2100041C patent/HUS2100041I1/hu unknown

Also Published As

Publication number	Publication date
US11873493B2 (en)	2024-01-16
DK3581654T3 (da)	2021-04-26
US20170306333A1 (en)	2017-10-26
CA2935220A1 (en)	2015-07-02
JP7109416B2 (ja)	2022-07-29
ES2875558T3 (es)	2021-11-10
EP3087184B1 (en)	2019-07-03
EP3581654A1 (en)	2019-12-18
CY2021022I1 (el)	2021-12-31
SMT202100325T1 (it)	2021-07-12
EP3892727A1 (en)	2021-10-13
JP2020036603A (ja)	2020-03-12
US20190211340A1 (en)	2019-07-11
HRP20210612T1 (hr)	2021-08-20
US9701966B2 (en)	2017-07-11
US20210230604A1 (en)	2021-07-29
HUE055470T2 (hu)	2021-11-29
FR21C1044I2 (fr)	2022-09-23
US20180291379A1 (en)	2018-10-11
EP3087184A4 (en)	2017-08-16
LTPA2021008I1 (2)	2021-09-27
LUC00218I2 (2)	2022-10-07
US10487330B2 (en)	2019-11-26
US10465195B2 (en)	2019-11-05
JP2017502668A (ja)	2017-01-26
LT3581654T (lt)	2021-06-25
US20190194665A1 (en)	2019-06-27
US9828606B2 (en)	2017-11-28
US10435692B2 (en)	2019-10-08
SI3581654T1 (sl)	2021-08-31
DK3087184T3 (da)	2019-07-29
FR21C1044I1 (2)	2021-11-19
ES2749855T3 (es)	2020-03-24
LTC3581654I2 (2)	2023-07-10
US20200002705A1 (en)	2020-01-02
EP3581654B1 (en)	2021-03-31
CY1124203T1 (el)	2021-12-31
FIC20210025I1 (fi)	2021-08-25
RS61892B1 (sr)	2021-06-30
US20150184160A1 (en)	2015-07-02
AU2014369850A1 (en)	2016-07-14
JP6886818B2 (ja)	2021-06-16
HUS2100041I1 (hu)	2021-10-28
AU2014369850B2 (en)	2021-04-08
PL3581654T3 (pl)	2021-09-13
EP3087184A1 (en)	2016-11-02
CY2021022I2 (el)	2021-12-31
AU2021201953A1 (en)	2021-04-29
WO2015100436A1 (en)	2015-07-02
NO2021038I1 (no)	2021-09-16
US11060093B2 (en)	2021-07-13

Publication	Publication Date	Title
PT3581654T (pt)	2021-06-02	Métodos e composições para a inibição específica de glicolato oxidase (hao1) por rna de cadeia dupla
BR112015021003A2 (pt)	2017-07-18	composições e métodos para a produção biológica de isopreno.
BR112014021204A2 (pt)	2017-07-11	método implantado por computador
PT3560954T (pt)	2021-09-07	Cadeia j modificada
DK3628670T3 (da)	2022-12-05	Saltform til ezh2-hæmning
CO6960518A2 (es)	2014-05-30	Conjunto de desgaste
EP2734532A4 (en)	2015-03-25	METALLIC COMPLEXES
DK2691685T3 (da)	2017-01-02	Rørledningsredskab
CU24164B1 (es)	2016-03-31	Inhibidores sustituidos de acetil-coa carboxilasa
LT3160952T (lt)	2021-05-10	Histono demetilazės inhibitoriai
DK2970429T3 (da)	2019-11-18	Gla-domæner som målmidler
DK3240767T3 (da)	2021-06-28	Mikroindkapslede nitrifikationshæmmersammensætninger
EP2753176A4 (en)	2015-10-21	HIV INHIBITORS
BR112014010997A2 (pt)	2017-06-06	processo para o preparo de ß-glicosídeos de c-arila
DK3137437T3 (da)	2020-01-27	Mikroindkapslet nitrifikationsinhibitorsammensætning
BR112013030897A2 (pt)	2017-06-06	composição.
EP2722366A4 (en)	2015-01-21	CURABLE COMPOSITION
BRDI7105327S (pt)	2013-12-03	Configuração aplicada em estojo para peças de dominó
DK3224355T3 (da)	2020-09-21	Enzym-inhibitorkomplekser
FI20145146A7 (fi)	2015-04-15	Laitteisto ketjukäyttöön
BR112013024067A2 (pt)	2018-04-24	ferramenta de raspar
EP2737900A4 (en)	2015-03-11	NDM-INHIBITOR
DE102012106209A8 (de)	2013-03-28	Turbinenschaufelschmiedeverfahren
ES1089054Y (es)	2013-12-03	Pala para aerogeneradores
FR2973705B1 (fr)	2013-08-02	Inhibiteur de tnf-alpha.